At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Nov 15, 2026 at 13:00 ET
Alpha Tau Medical announced updated interim results from its REGAIN trial of Alpha DaRT for recurrent glioblastoma, showing all eight treated patients alive, 100% objective response rate in evaluable patients (83.3% complete responses), and no unanticipated serious adverse events. The data were presented at the SNO annual meeting and suggest strong early efficacy in a devastating cancer with an average survival of 8 months.
- All eight treated patients alive as of November 11, 2026; median overall survival not reached
- Six evaluable patients: 100% objective response rate (5 complete responses, 1 partial response)
- No unanticipated serious adverse events; primary feasibility and safety endpoints met
- Trial enrolling toward 20 patients; initial discussions suggest data may support market submission
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access